You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid-19: BDR Pharmaceuticals plans to launch 400 mg Favipiravir tablets

The 'BDFAVI' 400 mg tablets will be priced at Rs 990 for a strip of 10 tablets, BDR Pharma said in a statement

Topics
Coronavirus

Press Trust of India  |  New Delhi 

Favipiravir, Umifenovir, atniviral, drugs, pharma, coronavirus, covid-19, sars, cov-2
Each tablet will cost Rs 99. In August, the company launched 200 mg Favipiravir tablets

Drug firm BDR Pharmaceuticals on Friday said it plans to launch 400 mg Favipiravir tablets, used for treating Covid-19 patients, in the country.

The 'BDFAVI' 400 mg tablets will be priced at Rs 990 for a strip of 10 tablets, BDR Pharma said in a statement. Each tablet will cost Rs 99. In August, the company launched 200 mg Favipiravir tablets.

"We aim to make BDFAVI available in sufficient quantities to meet the high demand for the drug in the Indian market to help curb the current crisis... introducing a higher dosage is an attempt to ensure a smoother experience to patients and caregivers," BDR Pharma CMD Dharmesh Shah said.

The company had received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate Covid-19 symptoms under the brand name BDFAVI, according to the statement.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, September 04 2020. 22:52 IST
RECOMMENDED FOR YOU
.